IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 72.63

Change

+0.58 (+0.80)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.49 (+1.01%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.72 (+1.04%)

USD 2.77B
FXH First Trust Health Care AlphaD..

+1.13 (+1.08%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

+0.45 (+0.52%)

USD 0.20B
IDNA iShares Genomics Immunology an..

+0.53 (+2.39%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.57 (+1.87%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+1.42 (+1.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.39 (+1.34%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.03 (+1.70%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.66 (+3.42%)

USD 6.67M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.51% 100% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.51% 100% F 89% A-
Trailing 12 Months  
Capital Gain 6.99% 81% B- 61% D-
Dividend Return 1.37% 88% B+ 24% F
Total Return 8.36% 86% B+ 54% F
Trailing 5 Years  
Capital Gain 46.41% 76% C+ 64% D
Dividend Return 9.54% 95% A 25% F
Total Return 55.95% 76% C+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 3.97% 48% F 47% F
Dividend Return 5.37% 57% F 44% F
Total Return 1.39% 100% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 15.27% 71% C- 66% D+
Risk Adjusted Return 35.16% 67% D+ 49% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike